Med. praxi. 2026;23(1):57-63 | DOI: 10.36290/med.2025.079

Medication and baverages

PharmDr. Josef Suchopár, MUDr. Štěpán Suchopár
DrugAgency, Praha

Proper co-ingestion of oral medications with an appropriate beverage is crucial to ensure their efficacy and safety. However, studies have shown that most patients do not take their medications with water as recommended, but instead use other drinks such as tea, fruit juices, or alcohol. This practice can lead to clinically significant drug interactions. These interactions most commonly arise from the inhibition of transporters such as OATP1A2 and OATP2B1, or the CYP3A4 enzyme, resulting in decreased or increased bioavailability of medications. For example, green tea, grapefruit juice, or orange juice may reduce the absorption of fexofenadine, lisinopril, or celiprolol by up to 99 %, or conversely significantly increase the systemic exposure of drugs metabolized by CYP3A4, such as simvastatin. This review summarizes the mechanisms underlying these interactions, the results of clinical and preclinical studies, and highlights the need for better patient and healthcare professional education regarding the importance of choosing an appropriate beverage when taking medications.

Keywords: medication co-ingestion, drug interactions, transport systems, OATP1A2, OATP2B1, PEPT1, CYP3A4, green tea, grapefruit juice, bioavailability, pharmacokinetics.

Received: July 7, 2025; Revised: August 12, 2025; Accepted: November 25, 2025; Published: March 3, 2026  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Suchopár J, Suchopár Š. Medication and baverages. Med. praxi. 2026;23(1):57-63. doi: 10.36290/med.2025.079.
Download citation

References

  1. Tesař O, Malý J, Malečová L, et al. Analýza podání léčiv ve vztahu k potravě a použitým nápojům u hospitalizovaných pacientů. Čes Slov Farm. 2023;72:303-310. Go to original source...
  2. Grangeon A, Clermont V, Barama A, et al. Determination of CYP450 expression levels in the human small intestine by mass spectrometry.based targeted proteomics. Int J Mol Sci. 2021;22(23):12791. Go to original source...
  3. Bailey D G, Spence J D, Edgar B, et al. Ethanol enhances the hemodynamic effects of felodipine. Clin Invest Med. 1989;12(6):357-362.
  4. Fuhr L M, Marok F Z, Fuhr U, et al. Physiologically based pharmacokinetic modeling of bergamottin and 6,7-dihydroxybergamottin to describe CYP3A4 mediated grapefruit drug interactions. Clin Pharmacol Ther. 2023;114(2):470-482. Go to original source...
  5. Lilja J J, Kivistö K T, Neuvonen P J. Grapefruit juice simvastatin interaction: effect on serum concentrations of sim. vastatin, simvastatin acid, and HMG.CoA reductase inhibitors. Clin Pharmacol Ther. 1998;64(5):477-483. Go to original source...
  6. Holmberg M T, Tornio A, Neuvonen M, et al. Grapefruit juice inhibits the metabolic activation of clopidogrel. Clin Pharmacol Ther. 2014;95(3):307-313. Go to original source...
  7. Holmberg M T, Tornio A, Hyvärinen, et al. Effect of grapefruit juice on the bioactivation of prasugrel. Br J Clin Pharmacol. 2015;80(1):139-145. Go to original source...
  8. Zaidenstein R, Soback S, Gips M, et al. Effect of grapefruit juice on the pharmacokinetics of losartan and its active metabolite E3174 in healthy volunteers. Ther Drug Monit. 2001;23(4):369-373. Go to original source...
  9. Abdelekawy K S Donia A M, Elbarby F, et al. Effects of grapefruit and pomegranate juices on the pharmacokinetic properties of dapoxetine and midazolam in healthy subjects. Eur J Drug Metab Pharmacokinet. 2017;42(3):397-405. Go to original source...
  10. Ohkubo A, Chida T, Kikuchi H, et al. Effects of tomato juice on the pharmacokinetics of CYP3A4.substrate drugs. Asian J Pharm Sci. 2017;12(5):464-469. Go to original source...
  11. Agarwal N, Mangla A. Elderberry interaction with pazopanib in a patient with soft tissue sarcoma: a case report and literature review. Mol Clin Oncol. 2024;20(5):36. Go to original source...
  12. Chen M, Zhou S-Y, Fabriaga E, et al. Food drug interactions precipitated by fruit juices other than grapefruit juice: an update review. J Food Drug Anal. 2018;26(2S):S61-S71. Go to original source...
  13. Misaka S, Kawabe K, Onoue S, et al. Green tea extract affects the cytochrome P450 3A activity and pharmacokinetics of simvastatin in rats. Drug Metab Pharmacokinet. 2013;28(6):514-518. Go to original source...
  14. Dresser G K, Schwarz U I, Wilkinson G R, et al. Coordinate induction of both cytochrome P4503A and MDR1 by St Johns wort in healthy subjects. Clin Pharmacol Ther. 2003;73(1):41-50. Go to original source...
  15. Matsuda K, Nishimura Y, Kurata N, et al. Effects of continuous ingestion of herbal teas on intestinal CYP3A in the rat. J Pharmacol Sci. 2007;103(2):214-221. Go to original source...
  16. Mohammed Abdul M I, Jiang X, Williams K M, et al. Pharmacodynamic interaction of warfarin with cranberry but not with garlic in healthy subjects. Br J Pharmacol. 2008;154(8):1691-1700. Go to original source...
  17. Suchopár J, Prokeš M. Lékové interakce. Obecné aspekty lékových interakcí: Drugagency; 2023. ISBN 978-80-908788-1-5.
  18. Clarke J D, Judson S M, Tian D-D, et al. Co-consuming green tea with raloxifene decreases raloxifene systemic exposure in healthy adult participants. Clin Transl Sci. 2023;16(10):1779-1790. Go to original source...
  19. Choi E J, Park J B, Yoon K D, et al. Evaluation of the in vitro/in vivo potential of five berries (bilberry, blueberry, cranberry, elderberry, and raspberry ketones) commonly used as herbal supplements to inhibit uridine diphospho-glucuronosyltransferase. Food Chem Toxicol. 2014;72:13-19. Go to original source...
  20. Wang M, Lu J, Li J, et al. Steviol glucuronidation and its potential interaction with UDP-glucuronosyltransferase 2B7 substrates. Food Chem Toxicol. 2014;64:135-143. Go to original source...
  21. El-Kattan A F. Oral bioavailability assessment: basics and strategies for drug discovery and development. Hoboken, NJ: John Wiley & Sons Inc.; 2017. ISBN 978-1118916933. Go to original source...
  22. Schoultz I, Keita Å V. The intestinal barrier and current techniques for the assessment of gut permeability. Cells. 2020;9(8):1909. Go to original source...
  23. Wu C-Y, Benet L Z. Predicting drug disposition via application of BCS: transport/absorption/elimination interplay and development of a biopharmaceutics drug disposition classi. fication system. Pharm Res. 2005;22(1):11-23. Go to original source...
  24. Benet L Z. The drug transporter metabolism alliance: uncovering and defining the interplay. Mol Pharm. 2009;6(6):1631-1643. Go to original source...
  25. Benet L Z, Broccatelli F, Oprea T I, et al. BDDCS applied to over 900 drugs. AAPS J. 2011;13(4):519-547. Go to original source...
  26. Shugarts S, Benet L Z. The role of transporters in the pharmacokinetics of orally administered drugs. Pharm Res. 2009;26(9):2039-2054. Go to original source...
  27. Lilja J J, Backman J T, Laitila J, et al. Itraconazole increases but grapefruit juice greatly decreases plasma concentrations of celiprolol. Clin Pharmacol Ther. 2003;73(3):192-198. Go to original source...
  28. Ieiri I, Doi Y, Maeda K, et al. Microdosing clinical study: pharmacokinetic, pharmacogenomic (SLCO2B1), and interaction (grapefruit juice) profiles of celiprolol following the oral microdose and therapeutic dose. J Clin Pharmacol. 2012;52(7):1078-1089. Go to original source...
  29. Tanaka S, Uchida S, Miyakawa S, et al. Comparison of inhibitory duration of grapefruit juice on organic anion transporting polypeptide and cytochrome P450 3A4. Biol Pharm Bull. 2013;36(12):1936-1941. Go to original source...
  30. Cvetkovic M, Leake B, Fromm M F, et al. OATP and P-glycoprotein transporters mediate the cellular uptake and excretion of fexofenadine. Drug Metab Dispos. 1999;27(8):866-871. Go to original source...
  31. Akamine Y, Miura M, Sunagawa S, et al. Influence of drug transporter polymorphisms on the pharmacokinetics of fexofenadine enantiomers. Xenobiotica [Internet]. 2010;40(11):782-789. Go to original source...
  32. Shirasaka Y, Mori T, Murata Y, et al. Substrate and dose dependent drug interactions with grapefruit juice caused by multiple binding sites on OATP2B1. Pharm Res. 2014;31(8):2035-2043. Go to original source...
  33. Crowe A, Wright C. The impact of P.glycoprotein mediated efflux on absorption of 11 sedating and less sedating antihistamines using Caco-2 monolayers. Xenobiotica. 2011;42(6):538-549. Go to original source...
  34. Shirasaka Y, Shichiri M, Mori T, et al. Major active components in grapefruit, orange, and apple juices responsible for OATP2B1.mediated drug interactions. J Pharm Sci. 2013;102(9):3418-3426. Go to original source...
  35. Bajraktari Sylejmani G, Weiss J. Potential risk of food.drug interactions: citrus polymethoxyflavones and flavanones as inhibitors of the organic anion transporting polypeptides (OATP) 1B1, 1B3, and 2B1. Eur J Drug Metab Pharmacokinet. 2020;45(6):809-815. Go to original source...
  36. Roth M, Timmermann B N, Hagenbuch B, et al. Interactions of green tea catechins with organic anion transporting polypeptides. Drug Metab Dispos. 2011;39(5):920-926. Go to original source...
  37. Morita T, Akiyoshi T, Tsuchitani T, et al. Inhibitory effects of cranberry juice and its components on intestinal OATP1A2 and OATP2B1: identification of avicularin as a novel inhibitor. J Agric Food Chem. 2022;70(10):3310-3320. Go to original source...
  38. Knütter I, Wollesky C, Kottra G, et al. Transport of angiotensin-converting enzyme inhibitors by H+/peptide trans. porters revisited. J Pharmacol Exp Ther. 2008;327(2):432-441. Go to original source...
  39. Misaka S, Yuko O, Uchida A, et al. Impact of green tea catechin ingestion on the pharmacokinetics of lisinopril in healthy volunteers. Clin Transl Sci. 2021;14(2):476-480. Go to original source...
  40. Kashihara Y, Ieri I, Yoshikado T, et al. Small dosing clinical study: pharmacokinetic, pharmacogenomic (SLCO2B1 and ABCG2), and interaction (atorvastatin and grapefruit juice) profiles of 5 probes for OATP2B1 and BCRP. J Pharm Sci. 2017;106(9):2688-2694. Go to original source...
  41. Kim T E, Ha N, Kim Y, et al. Effect of epigallocatechin 3-gallate, major ingredient of green tea, on the pharmacokinetics of rosuvastatin in healthy volunteers. Drug Des Devel Ther. 2017;11:1409-1416. Go to original source...
  42. Kondo A, Narumi K, Okuhara K, et al. Black tea extract and theaflavin derivatives affect the pharmacokinetics of rosuvastatin by modulating organic anion transporting polypeptide (OATP) 2B1 activity. Biopharm Drug Dispos. 2019;40(8):302-306. Go to original source...
  43. Cabrera C, Artacho R, Gimenéz R, et al. Beneficial effects of green tea - a review. J Am Coll Nutr. 2006;25(2):79-99. Go to original source...
  44. Zeng W, Lao S, Guo Y, et al. The influence of EGCG on the pharmacokinetics and pharmacodynamics of bisoprolol and a new method for simultaneous determination of EGCG and bisoprolol in rat plasma. Front Nutr. 2022;9:907986. Go to original source...
  45. Misaka S, Yatabe Y, Müller F, et al. Green tea ingestion gre. atly reduces plasma concentrations of nadolol in healthy subjects. Clin Pharmacol Ther. 2014;95(4):432-438. Go to original source...
  46. Abe O, Ono T, Sato H, et al. Role of (-)-epigallocatechin gallate in the pharmacokinetic interaction between nadolol and green tea in healthy volunteers. Eur J Clin Pharma. col. 2018;74(6):775-783. Go to original source...
  47. Bailey D G, Dresser G K, Bend J R, et al. Bergamottin, lime juice, and red wine as inhibitors of cytochrome P450 3A4 activity: comparison with grapefruit juice. Clin Pharmacol Ther. 2003;73(6):529-537. Go to original source...
  48. Malhotra S, Bailey D G, Paine M F, et al. Seville orange juice felodipine interaction: comparison with dilute grapefruit juice and involvement of furocoumarins. Clin Pharmacol Ther. 2001;69(1):14-23. Go to original source...
  49. Dresser G, Bailey D G, Carruthers S G, et al. Grapefruit juice felodipine interaction in the elderly. Clin Pharmacol Ther. 2000;68(1):28-34. Go to original source...
  50. Guo L.Q, Chen Q-Y, Wang X, et al. Different roles of pu. mmelo furanocoumarin and cytochrome P450 3A53 polymorphism in the fate and action of felodipine*. Curr Drug Metab. 2007;8(6):623-630. Go to original source...
  51. Theile D, Hohmann N, Kiemel D, et al. Clementine juice has the potential for drug interactions in vitro comparison with grapefruit and mandarin juice. Eur J Pharm Sci. 2017;97:247-256. Go to original source...
  52. Dresser G K, Bailey D G, Leake B F, et al. Fruit juices inhibit organic anion transporting Polypeptide-mediated drug uptake to decrease the oral availability of fexofenadine. Clin Pharmacol Ther. 2002;71(1):11-20. Go to original source...
  53. Misaka S, Yuko O, Taudte R V, et al. Exposure of fexofenadine, but not pseudoephedrine, is markedly decreased by green tea extract in healthy volunteers. Clin Pharmacol Ther. 2022;112(3):627-634. Go to original source...
  54. Kyriacou N M, Griss A S, McLachlan A J, et al. Green tea catechins as perpetrators of drug pharmacokinetic interactions. Clin Pharmacol Ther. 2025;118(1):45-61. Go to original source...
  55. Edgar B, Bailey D, Bergstrand R, et al. Acute effects of drinking grapefruit juice on the pharmacokinetics and dynamics of felodipine and its potential clinical relevance. Eur J Clin Pharmacol. 1992;42(3):313-317. Go to original source...
  56. Bailey D G, Dresser G, Malcolm O Arnold J, et al. Grapefruit-medication interactions: forbidden fruit or avoidable consequences? CMAJ. 2013;185(4):309-316. Go to original source...
  57. Lundahl J, Regårdh C G, Edgar B, et al. Relationship between time of intake of grapefruit juice and its effect on pharmacokinetics and pharmacodynamics of felodipine in healthy subjects. Eur J Clin Pharmacol. 1995;49(1-2):61-67. Go to original source...




Medicine for Practice

Madam, Sir,
please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

I declare:

  1. that I have met the above instruction
  2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited


No

Yes

If your statement is not true, please be aware
that brings the risk of danger to their health or the health of others.